Index high insulin resistance in pancreas-kidney transplantation contributes to poor long-term survival of the pancreas graft. 2015

V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
Department of Nephrology, H.U. Reina Sofía, Córdoba, Spain. Electronic address: mvitoriaprm@gmail.com.

BACKGROUND Pancreas-kidney transplantation (PKT) is the best therapeutic option for diabetic patients with end-stage renal failure. Peripheral insulin resistance and the percentage of remaining β-cells in the PKT have been little studied in medical literature. METHODS We analyzed PKT performed in our hospital from January 1992 to January 2014, with follow-up for 5 years. Metabolic values related to glycemic were studied, namely, proteinuria, peptide C, glucose, insulin, and glycosylated hemoglobin. We analyzed insulin resistance (homeostatic model assessment [HOMA]-IR), the percentage of remaining β-cells (HOMA-β), and the influence of these variables on the glycemic profile and graft survival. RESULTS In the study period, 156 simultaneous PKT were performed in our center. At 2 years posttransplantation, the median value of HOMA-IR kidney-pancreas was 4. We compared transplantation with lower HOMA-IR (<4) and higher HOMA-IR (>4). HOMA-β (36 [26-67] vs 29 [14-42]; P = .04), glucose (86 [80-90] vs 81 [74-89]; P = .018), and body mass index (BMI; 24 [21-27] vs 21 [19-24]; P = .013) were greater in the group HOMA-IR>4 versus HOMA-IR<4 group, respectively, after 3 months. These differences in glycemic profile were maintained until the first year after transplantation. At 2 and 5 years of follow-up, the HOMA-IR>4 group showed higher glucose levels and greater BMI, but not differences in HOMA-β. At 1 and 5 years posttransplantation, pancreatic graft survival in the HOMA-IR>4 group (82.9% vs 92.5%) was lower compared with the HOMA-IR<4 group (67% vs 87.5%; P = .016). CONCLUSIONS PKT exhibit an altered glycemic profile in the posttransplantation follow-up associated with the percentage of remaining β-cells and peripheral insulin resistance. PKT patients with peripheral insulin resistance showed decreased pancreatic graft survival.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005260 Female Females

Related Publications

V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
February 1993, Transplantation proceedings,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
December 2014, Transplantation,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
May 2014, Transplant immunology,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
January 1989, Diabetes,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
April 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
January 2012, Clinical transplants,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
January 2015, Clinical transplants,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
June 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
October 1987, Transplantation proceedings,
V Pendón-Ruiz de Mier, and M D Navarro Cabello, and S Martínez Vaquera, and M Lopez-Andreu, and M L Aguera Morales, and A Rodriguez-Benot, and J Ruiz Rabelo, and P Campos Hernandez, and M J Requena Tapia, and P Aljama Garcia
May 2004, Transplantation proceedings,
Copied contents to your clipboard!